ACAD
Price
$14.79
Change
+$0.17 (+1.16%)
Updated
Apr 24, 02:14 PM (EDT)
Capitalization
2.39B
19 days until earnings call
PHMMF
Price
$88.18
Change
-$13.90 (-13.62%)
Updated
Mar 27 closing price
Capitalization
1.5B
Ad is loading...

ACAD vs PHMMF

Header iconACAD vs PHMMF Comparison
Open Charts ACAD vs PHMMFBanner chart's image
ACADIA Pharmaceuticals
Price$14.79
Change+$0.17 (+1.16%)
Volume$300
Capitalization2.39B
Pharma Mar SA
Price$88.18
Change-$13.90 (-13.62%)
Volume$2.19K
Capitalization1.5B
ACAD vs PHMMF Comparison Chart
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACAD vs. PHMMF commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a StrongBuy and PHMMF is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (ACAD: $14.62 vs. PHMMF: $88.18)
Brand notoriety: ACAD and PHMMF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 94% vs. PHMMF: 227%
Market capitalization -- ACAD: $2.39B vs. PHMMF: $1.5B
ACAD [@Biotechnology] is valued at $2.39B. PHMMF’s [@Biotechnology] market capitalization is $1.5B. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whilePHMMF’s FA Score has 1 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • PHMMF’s FA Score: 1 green, 4 red.
According to our system of comparison, PHMMF is a better buy in the long-term than ACAD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 6 TA indicator(s) are bullish.

  • ACAD’s TA Score: 6 bullish, 2 bearish.

Price Growth

ACAD (@Biotechnology) experienced а +0.34% price change this week, while PHMMF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.07%. For the same industry, the average monthly price growth was -6.06%, and the average quarterly price growth was -12.59%.

Reported Earning Dates

ACAD is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+7.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($2.39B) has a higher market cap than PHMMF($1.5B). PHMMF has higher P/E ratio than ACAD: PHMMF (51.94) vs ACAD (10.55). PHMMF YTD gains are higher at: 8.774 vs. ACAD (-20.327). ACAD has higher annual earnings (EBITDA): 100M vs. PHMMF (21.2M). ACAD has more cash in the bank: 756M vs. PHMMF (155M). PHMMF (51.1M) and ACAD (52M) have identical debt. ACAD has higher revenues than PHMMF: ACAD (958M) vs PHMMF (175M).
ACADPHMMFACAD / PHMMF
Capitalization2.39B1.5B159%
EBITDA100M21.2M472%
Gain YTD-20.3278.774-232%
P/E Ratio10.5551.9420%
Revenue958M175M547%
Total Cash756M155M488%
Total Debt52M51.1M102%
FUNDAMENTALS RATINGS
ACAD vs PHMMF: Fundamental Ratings
ACAD
PHMMF
OUTLOOK RATING
1..100
1437
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
3
Undervalued
PROFIT vs RISK RATING
1..100
10072
SMR RATING
1..100
2559
PRICE GROWTH RATING
1..100
7737
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PHMMF's Valuation (3) in the null industry is somewhat better than the same rating for ACAD (58) in the Biotechnology industry. This means that PHMMF’s stock grew somewhat faster than ACAD’s over the last 12 months.

PHMMF's Profit vs Risk Rating (72) in the null industry is in the same range as ACAD (100) in the Biotechnology industry. This means that PHMMF’s stock grew similarly to ACAD’s over the last 12 months.

ACAD's SMR Rating (25) in the Biotechnology industry is somewhat better than the same rating for PHMMF (59) in the null industry. This means that ACAD’s stock grew somewhat faster than PHMMF’s over the last 12 months.

PHMMF's Price Growth Rating (37) in the null industry is somewhat better than the same rating for ACAD (77) in the Biotechnology industry. This means that PHMMF’s stock grew somewhat faster than ACAD’s over the last 12 months.

PHMMF's P/E Growth Rating (100) in the null industry is in the same range as ACAD (100) in the Biotechnology industry. This means that PHMMF’s stock grew similarly to ACAD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACAD
RSI
ODDS (%)
Bullish Trend 2 days ago
59%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
71%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 10 days ago
73%
Declines
ODDS (%)
Bearish Trend 3 days ago
72%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
64%
Aroon
ODDS (%)
Bearish Trend 2 days ago
75%
View a ticker or compare two or three
Ad is loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSIFX28.43N/A
N/A
Goldman Sachs International Eq ESG A
RSLFX64.96N/A
N/A
American Funds SMALLCAP World R5
LBISX19.29N/A
N/A
BrandywineGLOBAL Div US Large Value IS
KINCX76.13N/A
N/A
Kinetics Internet Adv C
HRSRX56.71N/A
N/A
Hood River Small-Cap Growth Investor

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with RGNX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
+1.88%
RGNX - ACAD
48%
Loosely correlated
+13.43%
HRTX - ACAD
44%
Loosely correlated
+2.33%
XNCR - ACAD
42%
Loosely correlated
+2.07%
RCKT - ACAD
41%
Loosely correlated
+2.44%
COGT - ACAD
41%
Loosely correlated
+3.00%
More

PHMMF and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHMMF has been loosely correlated with DRUG. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if PHMMF jumps, then DRUG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHMMF
1D Price
Change %
PHMMF100%
N/A
DRUG - PHMMF
42%
Loosely correlated
+1.79%
CSCI - PHMMF
22%
Poorly correlated
+2.47%
KALV - PHMMF
21%
Poorly correlated
+1.22%
ACAD - PHMMF
21%
Poorly correlated
+1.88%
AVCTF - PHMMF
20%
Poorly correlated
N/A
More